In this issue, the HSA editorial team brings you safety updates on the use of montelukast and pirfenidone, sibutramine-induced AE characteristics due to adulterated health products, the voluntary withdrawal of Esmya TM Tablet 5mg in Singapore and a case study of Miller Fisher Syndrome in a patient. We would also like to remind healthcare professionals on vaccine AE reporting and to verify HLA-B*1502 status in new patients of Asian ancestry before starting carbamazepine.
We will like to share with you the following article by HSA:
(Click the title of the article below to read more)
The news bulletin is posted on the MOH Health Professional Portal and HSA’s website.
